Condition: Asthma
Interventions: Device: ELLIPTA DPI; Device: GSK MDI; Device: AZ MDI
Sponsor: GlaxoSmithKline
Not yet recruiting – verified June 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With Asthma
Condition: Asthma
Interventions: Drug: Placebo ELLIPTA inhaler; Other: Questionnaire
Sponsor: GlaxoSmithKline
Not yet recruiting – verified October 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Pharmacists Can Correct Asthma Controller Medication Underuse – Pharmacy Times
The Pharmaceutical Journal |
Pharmacists Can Correct Asthma Controller Medication Underuse
Pharmacy Times A study published May 4, 2015 in Pediatrics analyzed data from 35,467 asthma medication prescriptions filled between January 31, 2010, and January 30, 2012, for children aged 2 to 17 years in Hamilton County, Ohio. Classifying the asthma medications as … Pharmacies could play a role in reducing asthma-related deaths |
View full post on asthma – Google News
Critical Handling Errors With DPI Use That May Influence Correct Inhalation and Drug Uptake-delivery, in Asthma and COPD Patients.
Conditions: Asthma; COPD
Intervention:
Sponsor: Elpen Pharmaceutical Co. Inc.
Not yet recruiting – verified January 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
CORRECT: Vectura Licenses Patents To GlaxoSmithKline – Wall Street Journal
 Stockopedia |
CORRECT: Vectura Licenses Patents To GlaxoSmithKline
Wall Street Journal VX) generics unit Sandoz handed back the US rights to VR315, a generic version of an asthma drug, to Vectura. Analysts said it signaled Sandoz wasn't sure … INTERVIEW: Vectura Patents For GSK's 573719 And 642444 Vectura and GlaxoSmithKline sign agreement over asthma patents Vectura boosted by deal with GSK worth over $30 million upfront plus royalties … |
View full post on asthma – Google News